ImmunityBio Inc. (IBRX)
3.04
-0.10 (-3.18%)
At close: Mar 31, 2025, 3:38 PM
ImmunityBio Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 14.74M | 622K | 240K | 934K | 605K | 2.2M | 47K | 45K | 44K | 236K | 641K | 600K |
| Cost of Revenue | n/a | n/a | 24.19M | n/a | 9.15M | 9.01M | -3.11M | n/a | n/a | n/a | n/a | 253K |
| Gross Profit | 14.74M | 622K | -23.95M | 934K | -8.54M | -6.81M | 3.16M | 45K | 44K | 236K | 641K | 347K |
| Operating Income | -344.18M | -362.25M | -351.3M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.5M | -238.88M | -6.21M | -2.27M |
| Interest Income | 2.4M | 863K | 2.71M | 836K | 1.73M | 2.76M | n/a | n/a | n/a | n/a | n/a | 2K |
| Pretax Income | -413.56M | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Net Income | -413.56M | -583.2M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Selling & General & Admin | 168.78M | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Research & Development | 190.14M | 232.37M | 248.15M | 195.96M | 139.51M | 112M | 53.42M | 39.78M | 26.55M | 11.43M | 1.59M | 446K |
| Other Expenses | n/a | 886K | -736K | 193K | 1.49M | -534K | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 358.93M | 362.87M | 350.86M | 331.21M | 210.82M | 158.45M | 88.88M | 93.6M | 120.94M | 237.64M | 5.92M | 2.87M |
| Interest Expense | 131.66M | 129.2M | 63.52M | 14.85M | 9.07M | 5.92M | 433K | 618K | 66K | n/a | n/a | 463K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 7.07M | -3.3M | -1M | -1.47M | n/a | n/a |
| Cost & Expenses | 358.93M | 362.87M | 350.86M | 331.21M | 210.82M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Income Tax | n/a | -40K | 34K | 9K | -1.85M | -105K | -503K | -493K | -572K | -301K | 1K | 1K |
| Shares Outstanding (Basic) | 697.31M | 508.64M | 399.9M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Shares Outstanding (Diluted) | 700.44M | 508.64M | 399.9M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| EPS (Basic) | -0.59 | -1.15 | -1.04 | -0.9 | -0.59 | -0.42 | -1.22 | -1.2 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS (Diluted) | -0.59 | -1.15 | -1.04 | -0.9 | -0.59 | -0.42 | -1.22 | -1.2 | -1.47 | -3.31 | -0.02 | -2.57 |
| EBITDA | -264.43M | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| Depreciation & Amortization | 17.55M | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.55M | 5.57M | 3.61M | 1.47M | 128K | 4K |